After receiving some analyst love, shares of TherapeuticsMD (NASDAQ:TXMD), a commercial-stage biopharma focused on women's health, rose 13% as of 3:35 p.m. EDT Tuesday.
Investors can thank Annabel Samimy -- an analyst at Stifel Financial -- for today's move. Samimy published a bullish note after attending TherapeuticsMD's recent analyst day stating that she had "high confidence in the launch of Imvexxy." Imvexxy is the company's recently approved treatment for dyspareunia, which is a condition that causes some menopausal women to experience vaginal pain during sex.
Samimy also stated that she was excited about the potential approval and commercial launch of TX001HR, which is a drug that is being developed as a potential treatment for vasomotor symptoms related to menopause.
The optimism caused Samimy to reiterate her "Buy" rating on the shares and reaffirm her $20 price target. For context, TherapeuticsMD's stock closed Monday's trading session at $5.82. Traders responded to the positive note by bidding up shares.
Now that Imvexxy has officially received FDA approval, it is possible that TherapeuticxMD's troubles might finally be in the past. However, the company still has to execute against its market opportunity.
I think there is plenty of reason to remain optimistic about Imvexxy, but it is still too early to draw any conclusions. For that reason, my plan is to approach this stock with a wait-and-see mindset.